Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults

Journal of Infection and Chemotherapy

Volumn 21, Issue 3, 2014, Pages 153-160

  Miyashita, Naoyuki ^a   Kawai, Yasuhiro ^a   Inamura, Norikazu ^a   Tanaka, Takaaki ^a   Akaike, Hiroto ^a   Teranishi, Hideto ^a   Wakabayashi, Tokio ^a   Nakano, Takashi ^a   Ouchi, Kazunobu ^a   Okimoto, Niro ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Interleukin 18; Lactate dehydrogenase; Mycoplasma pneumoniae; Refractory pneumonia; Severe pneumonia; Steroid therapy

Indexed keywords

BETA LACTAM ANTIBIOTIC; BIOLOGICAL MARKER; CLINDAMYCIN; INTERLEUKIN 18; LACTATE DEHYDROGENASE; MACROLIDE; METHYLPREDNISOLONE; MINOCYCLINE; PREDNISOLONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MULTICENTER STUDY (TOPIC); MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; STEROID THERAPY; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PATHOGENICITY; PNEUMONIA, MYCOPLASMA; STANDARDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTERLEUKIN-18; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA; STEROIDS; YOUNG ADULT;

EID: 84942426402     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2014.10.008     Document Type: Article

References (30)

1. Waites K.B., Talkington D.F. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004, 17:697-728.
2. National Institute of Health. Infectious Disease Surveillance Center. Mycoplasma pneumoniae pneumonia. http://idsc.nih.go.jp/idwr/kanja/weeklygraph/18myco.html.
3. Miyashita N., Obase Y., Ouchi K., Kawasaki K., Kawai Y., Kobashi Y., et al. Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit. J Med Microbiol 2007, 56:1625-1629.
4. Izumikawa K., Izumikawa K., Takazono T., Kosai K., Morinaga Y., Nakamura S., et al. Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia: a review of the Japanese literature. J Infect Chemother 2014, 20:181-185.
5. Lee K.-Y., Lee H.-S., Hong J.-H., Lee M.-H., Lee J.-S., Burgner D., et al. Role of predonisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 2006, 41:263-268.
6. Tamura A., Matsubara K., Tanaka T., Nigami H., Yura K., Fukaya T. Methylpredonisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect 2008, 57:223-228.
7. Lu A., Wang L., Zhang X., Zhang M. Combined treatment for child refractory Mycoplasma pneumoniae pneumonia with ciproxacin and glucocorticoid. Pediatr Pulmonol 2011, 46:1093-1097.
8. Luo Z., Luo J., Liu E., Xu X., Liu Y., Zeng F., et al. Effects of prednisolone on Mycoplasma pneumoniae pneumonia in chirdren. Pediatr Pulmonol 2013, [Epub ahead of print]. 10.1002/ppul.22752.
9. You S.Y., Jwa H.J., Yang E.A., Kil H.R., Lee J.H. Effects of methylprednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in children. Allergy Asthma Immunol Res 2014, 6:22-26.
10. Radisic M., Torn A., Gutierrez P., Defranchi H.A., Pardo P. Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment. Clin Infect Dis 2000, 31:1507-1511.
11. Shimizu T., Kida Y., Kuwano K. Cytoadherence-dependent induction of inflammatory responses by Mycoplasma pneumoniae. Immunology 2011, 133:51-61.
12. Narita M., Tanaka H., Abe S., Yamada S., Kubota M., Togashi T. Close association between pulmonary disease manifestation in Mycoplasma pneumoniae infection and enhanced local production of interleukin-18 in the lung, independent of gamma interferon. Clin Diagn Lab Immunol 2000, 7:909-914.
13. Tanaka H., Narita M., Teramoto S., Sakai T., Oashi K., Igarashi T., et al. Role of interleukin-18 and type I cytokines in the development of Mycoplasma pneumoniae pneumonia in adults. Chest 2002, 121:1493-1497.
14. Oishi T., Narita M., Matsui K., Shirai T., Matsuo M., Negishi J., et al. Clinical implications of interleukin-18 levels in pediatric patients with Mycoplasma pneumoniae pneumonia. J Infect Chemother 2011, 17:803-806.
15. Inamura M., Miyashita N., Hasegawa S., Kato A., Fukuda Y., Saitoh A., et al. Management of refractory Mycoplasma pneumoniae pneumonia: utility of measuring serum lactate dehydrogenase level. J Infect Chemother 2014, 20:270-273.
16. Tagliabue C., Salvatore C.M., Techasaensiri C., Mejias A., Torres J.P., Katz K., et al. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis 2008, 198:1180-1188.
17. Hirano S., Wada H., Nakagaki K., Saraya T., Kurai D., Mikura S., et al. Inflammation provoked Mycoplasma pneumoniae exact: implications for combination treatment with clarithromycin and dexamethasone. FEMS Immunol Med Microbiol 2011, 62:182-189.
18. The committee for the Japanese Respiratory Society Guidelines in Management of Respiratory Infections The Japanese Respiratory Society guideline for the management of community-acquired pneumonia in adults. Respirology 2006, 11:79-133.
19. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44:S27-S72. American Thoracic Society.
20. Miyashita N., Kawai Y., Yamaguchi T., Ouchi K., Oka M. Clinical potential of diagnostic methods for the rapid diagnosis of Mycoplasma pneumoniae pneumonia in adults. Eur J Clin Microbiol Infect Dis 2011, 30:439-446. Atypical Pathogen Study Group.
21. Miyashita N., Kawai Y., Akaike H., Ouchi K., Hayashi T., Kurihara T., et al. Influence of age in the clinical differentiation of atypical pneumonia in adults. Respirology 2012, 17:1073-1079.
22. Miyashita N., Akaike H., Teranishi H., Ouchi K., Okimoto N. Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility and therapeutic efficacy. Antimicrob Agents Chemother 2013, 57:5181-5185.
23. Kawai Y., Miyashita N., Kubo M., Akaike H., Kato A., Nishizawa Y., et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. Antimicrob Agents Chemother 2013, 57:2252-2258.
24. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
25. Miyashita N., Sugiu T., Kawai K., Oda K., Yamaguchi T., Ouchi K., et al. Radiographic features of Mycoplasma pneumoniae pneumonia: differential diagnosis and performance timing. BMC Med Imaging 2009, 9:7.
26. Principi N., Bianchini S., Baggi E., Esposito S. No evidence for the effectiveness of systemic corticosteroids in acute pharyngitis, community-acquired pneumonia and acute otitis media. Eur J Clin Microbiol Infect Dis 2013, 32:151-160.
27. Shafiq M., Mansoor M.S., Khan A.A., Sohail M.R., Murad M.H. Adjuvant steroid therapy in community-acquired pneumonia: a systemic review and meta-analysis. J Hosp Med 2013, 8:68-75.
28. Povoa P., Salluh J.I. What is the role of steroids in pneumonia therapy?. Curr Opin Infect Dis 2012, 25:199-204.
29. Sawa T., Kimura S., Hosono-Honda N., Fujita K., Yoshizawa S., Harada Y., et al. Diagnostic usefulness of ribosomal protein L7/L12 for pneumococcal pneumonia in a mouse model. J Clin Microbiol 2013, 51:70-76.
30. Gotoh S., Nishimura N., Takahashi O., Shiratsuka H., Horinouchi H., Ono H., et al. Adrenal function in patients with community-acquired pneumonia. Eur Respir J 2008, 31:1269-1273.